TRI-PRIME GENE

With robust R&D capabilities, Tri-Prime Gene has been a postdoctoral research center since 2001 being approved by China's Ministry of Personnel. The company's development pipeline includes several clinical-stage novel drug candidates achieving global standards of innovation. Tri-Prime Gene holds 50+ patents in China, the United States, and other countries. Tri-Prime Gene has undertaken more than 20 national and municipal key scientific research projects, and has obtained 10+ new drug certificates and production approvals, demonstrating its strong innovation capabilities and industry-leading position... Founded in 1992, Tri-Prime Gene holds the distinction of being China's first pharmaceutical company being named for its proprietary genetically engineering technologies. It was co-founded by its inaugural Chairman, Academician Hou Yunde, and inaugural General Manager, Mr. Cheng Yongqing. The company's core product, Recombinant Human Interferon α1b (Hapgen®), represents China's first..